QVT Financial Portfolio holdings
QVT Financial manages private funds and began as a trading group inside an investment bank; since 2018 it has mainly managed the money of its own principals and a handful of private investors. That change gave it a steadier source of money and room to hold more concentrated positions for longer. Its strategies include long and short stock trades, convertible securities, credit trades and hedges against sharp market drops. Its principal owners include chief executive Daniel Gold, Nicholas Brumm, Arthur Chu and Tracy Fu.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$66.1M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$9.22M |
| 3 |
Nexstar Media Group
NXST
|
+$8.17M |
| 4 |
RAAQ
Real Asset Acquisition Corp
RAAQ
|
+$6.94M |
| 5 |
Radcom
RDCM
|
+$6.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roivant Sciences
ROIV
|
+$42.5M |
| 2 |
Amicus Therapeutics
FOLD
|
+$10.1M |
| 3 |
Birkenstock
BIRK
|
+$9.8M |
| 4 |
Goldman Sachs
GS
|
+$7.82M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$7.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.38% |
| 2 | Miscellaneous | 16.75% |
| 3 | Technology | 9.72% |
| 4 | Financials | 7.99% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Roivant Sciences
ROIV
$26.7B
| $840M | 49.36% |
23,723,074
-1,438,163
| -6% | -$42.5M |
2021 Q4
18 quarters
|
|
|
2
State Street SPDR S&P 500 ETF Trust
SPY
$802B
| $71.6M | 4.21% |
95,837
+91,141
| +1,941% | +$66.1M |
2026 Q1
1 quarter
|
|
3
Okeanis Eco Tankers
ECO
$3.96B
| $64.2M | 3.78% |
1,423,997
| – | – |
2024 Q1
9 quarters
|
|
4
PUT
Jackson Financial
JXN
$9.14B
| $63.1M | 3.71% |
+616,600
| New | +$66.8M |
2026 Q2
0 quarters
|
|
5
PUT
Carvana
CVNA
$75.3B
| $54M | 3.17% |
820,000
-30,000
| -4% | -$2.12M |
2025 Q2
4 quarters
|
|
6
Allot
ALLT
$428M
| $49.5M | 2.91% |
5,598,293
| – | – |
2021 Q2
20 quarters
|
|
|
7
Goldman Sachs
GS
$260B
| $48.8M | 2.87% |
48,286
-8,016
| -14% | -$7.82M |
2018 Q4
30 quarters
|
|
8
Anterix
ATEX
$1.78B
| $39.5M | 2.32% |
383,941
-120,000
| -24% | -$7.04M |
2015 Q1
45 quarters
|
|
|
9
Invesco QQQ Trust
QQQ
$466B
| $39.1M | 2.3% |
53,044
-10,451
| -16% | -$7.19M |
2025 Q4
2 quarters
|
|
|
10
Nexstar Media Group
NXST
$5.28B
| $35.5M | 2.09% |
198,891
+43,610
| +28% | +$8.17M |
2025 Q4
2 quarters
|
|
|
11
Berkshire Hathaway Class B
BRK.B
$1.16T
| $33.6M | 1.97% |
67,124
+19,178
| +40% | +$9.22M |
2019 Q3
27 quarters
|
|
12
Nelnet
NNI
$4.38B
| $30.9M | 1.81% |
231,414
| – | – |
2021 Q3
19 quarters
|
|
13
Apple
AAPL
$5.03T
| $26.3M | 1.54% |
90,765
| – | – |
2025 Q4
2 quarters
|
|
14
NVIDIA
NVDA
$4.94T
| $25M | 1.47% |
125,158
-12,029
| -9% | -$2.47M |
2025 Q2
4 quarters
|
|
15
New York Times
NYT
$11.3B
| $22.2M | 1.3% |
316,947
| – | – |
2015 Q2
44 quarters
|
|
16
Whitehawk Therapeutics
WHWK
$185M
| $21.1M | 1.24% |
4,615,709
| – | – |
2024 Q4
6 quarters
|
|
17
Infleqtion Inc
INFQ
$2B
| $15.6M | 0.92% |
1,170,881
-83,339
| -7% | -$1.15M |
2026 Q1
1 quarter
|
|
18
Liberty Latin America Class C
LILAK
$1.64B
| $15.2M | 0.89% |
1,949,734
+25,320
| +1% | +$184K |
2023 Q1
13 quarters
|
|
|
RAAQ
19
DELISTED
Real Asset Acquisition Corp
RAAQ
| $15.1M | 0.89% |
1,398,027
+635,342
| +83% | +$6.94M |
2026 Q1
1 quarter
|
|
20
Magnite
MGNI
$3.08B
| $14.2M | 0.83% |
747,437
+293,527
| +65% | +$4.2M |
2025 Q4
2 quarters
|
|
21
Microsoft
MSFT
$3.88T
| $14.1M | 0.83% |
37,710
-7,829
| -17% | -$3.17M |
2025 Q4
2 quarters
|
|
22
Zura Bio
ZURA
$389M
| $11.2M | 0.66% |
1,895,153
+584,560
| +45% | +$2.78M |
2026 Q1
1 quarter
|
|
23
CarMax
KMX
$7.89B
| $10.6M | 0.62% |
200,000
-60,903
| -23% | -$2.65M |
2025 Q3
3 quarters
|
|
24
PUT
MetLife
MET
$63.6B
| $8.46M | 0.5% |
+100,000
| New | +$8.06M |
2026 Q2
0 quarters
|
|
25
Noble Corp
NE
$7.82B
| $7.78M | 0.46% |
208,634
| – | – |
2024 Q3
7 quarters
|
|
Similar funds
QVT Financial's Q2 2026 Portfolio in Review
As of Q2 2026, QVT Financial held 94 positions worth $1.7B, up 25% from $1.37B the previous quarter. Its ten largest holdings account for 77% of the portfolio.
QVT Financial's Q2 2026 filing shows 17 new, 14 increased, 26 reduced and 13 closed positions. Its largest new stake was Radcom: 445,265 shares worth $6.28M. The largest sale was Roivant Sciences, an estimated $42.5M.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 55% a quarter earlier, followed by Miscellaneous and Technology.
- QVT Financial's largest Q2 2026 buy was Radcom: 445,265 shares worth $6.28M.
- QVT Financial added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $66.1M increase.
- QVT Financial's biggest Q2 2026 reduction was Roivant Sciences, cutting an estimated $42.5M.
- QVT Financial fully exited Amicus Therapeutics in Q2 2026, selling an estimated $10.1M.
- QVT Financial's ten largest holdings make up 77% of its $1.7B portfolio in Q2 2026.
- QVT Financial opened 17 new positions and closed 13 in Q2 2026.
- QVT Financial's portfolio value rose 25% quarter-over-quarter to $1.7B.
Based on QVT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.